Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Q1 2021 Results Investor presentation 1 Investor Relations │ Q1 2021 Results Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding the impact of the COVID-19 pandemic on certain therapeutic areas including dermatology, ophthalmology, our breast cancer portfolio, some newly launched brands and the Sandoz retail and anti-infectives business, and on drug development operations; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group’s liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding our collaboration with Molecular Partners to develop, manufacture and commercialize potential medicines for the prevention and treatment of COVID- 19 and our joining of the industry-wide efforts to meet global demand for COVID-19 vaccines and therapeutics by leveraging our manufacturing capacity and capabilities to support the production of the Pfizer-BioNTech vaccine and to manufacture the mRNA and bulk drug product for the vaccine candidate CVnCoV from CureVac. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward- looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of the COVID-19 pandemic on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics by mid 2021; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this presentation; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, including the in-licensing of tislelizumab from BeiGene, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. DARPin® is a registered trademark of Molecular Partners AG. 2 Novartis Q1 Results | April 27, 2021 | Novartis Investor Presentation 2 Investor Relations │ Q1 2021 Results ParticipantsParticipants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Participants Vas Narasimhan John Tsai Chief Executive Officer Head of Global Drug Development and CMO Harry Kirsch Richard Saynor Chief Financial Officer CEO, Sandoz Marie-France Tschudin Tom Kendris President, Novartis Pharmaceuticals Chief Legal Officer Ad Interim Susanne Schaffert Samir Shah President, Novartis Oncology Global Head Investor Relations 3 Novartis Q1 Results | April 27, 2021 | Novartis Investor Presentation 3 Investor Relations │ Q1 2021 Results Participants CompanyCompany overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Vas Narasimhan Chief Executive Officer Company overview 4 Novartis Q1 Results | April 27, 2021 | Novartis Investor Presentation 4 Investor Relations │ Q1 2021 Results Participants CompanyCompany overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Summary of Q1 performance Growth1,2: growth drivers continue momentum 1 Innovation: confident in our leading pipeline 3 § Group sales -2%; Ex. PY forward purchasing +1% Entresto® FDA expanded indication in chronic heart failure (LVEF below normal) § IM sales in line vs. PY; Ex. PY forward purchasing +3% LNP023 Ph2b IgAN met primary endpoint enabling Ph3 initiation § Sandoz sales -13%; Ex. PY forward purchasing -9% 177Lu-PSMA-617 Ph3 VISION study met both primary endpoints (mCRPC) Tislelizumab In-licensing closed. Ph3 positive results in esophageal and NSCLC Productivity1,2: strong underlying core OpInc of IM 2 ESG: progress recognized 4 § Core operating income -8%; Ex. PY forwarding purchasing -1% #2 #13 § IM core operating income -1%; Ex. PY forward purchasing +6% § Recognized Novartis for systematic approach to access planning § IM core margin 36.3% (-0.5%pt cc); Ex. PY forward purchasing +1%pt § The only company amongst peers with a “Low Risk” § Integration of ESG in US and clinical trial diversity All growth % in cc IM – Innovative Medicines division 1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 36 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year 2. Growth excluding prior year COVID-19 related forward purchasing is a non-IFRS measure, an explanation for this measure can be found on page 44 of the Condensed Interim Financial Report 3. Within peer group as defined by Sustainalytics 5 Novartis Q1 Results | April 27, 2021 | Novartis Investor Presentation 5 Investor Relations │ Q1 2021 Results Participants CompanyCompany overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 1. GROWTH Key growth drivers and launches continue momentum in Q1 Key growth driver sales momentum1 Driving portfolio rejuvenation 3% growth ex. PY Q1Sales Sales Growth vs. PY Growth vs. PY forward purchasing USD Million USD Million cc Key growth drivers and launches 48% of IM sales, growing 20% in Q1 1,2 789 220 34% (reported in-line) ® 319 149 81% 48% Beovu Innovative Medicines Q1 Kesimpta® net sales growth, % cc 1,053 123 11% Mayzent® ® 463 60 13% 41% Piqray 3% Xiidra® 151 58 55% Lutathera® ® 50 50 nm 31% Kymriah Kisqali® 363 ® 45 8% 24% Ilaris Zolgensma® 256 43 20% Jakavi® ® 195 34 19% Tafinlar+Mekinist 0% Promacta® 335 28 3% Entresto® Reported Ex. PY 393 27 4% Cosentyx® forward 1 Q1 2018 Q1 2019 Q1 2020 Q1 2021 Other 55 25 80% purchasing 1. Includes Xolair®, Aimovig®, Adakveo®, Tabrecta ®, nm – not meaningful Luxturna® , Enerzair ®, Atectura® and Leqvio® 1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 36 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Growth excluding prior year COVID-19 related forward purchasing is a non-IFRS measure, an explanation for this measure can be found on page 44 of the Condensed Interim Financial Report 6 Novartis Q1 Results | April 27, 2021 | Novartis Investor Presentation 6 Investor Relations │ Q1 2021 Results Participants CompanyCompany overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 2. PRODUCTIVITY Confident to deliver on Innovative Medicines (IM) core margin target; underlying IM Core OpInc +6% ex. PY forward purchasing Innovative Medicines Q1 IM performance